Skip to main content
Premium Trial:

Request an Annual Quote

Belgium's Walloon Region Funds $2.2M to Explore Role of DNA Hydroxymethylation in Breast Cancer

NEW YORK (GenomeWeb) – Belgium's Walloon Region has earmarked about €1.6 million ($2.2 million) to a project aimed at exploring the role DNA hydroxymethylation may play in breast cancer, the Université Libre de Bruxelles announced today.

The aim of the CANDx project is to develop new diagnostic and therapeutic tools for aggressive breast cancer tumors. François Fuks, head of ULB's Laboratory of Cancer Epigenetics, is coordinating the project.

DNA hydroxymethylation is a form of DNA epigenetic modification that is sometimes referred to as the sixth base. Alterations to the hydroxymethylation of DNA cytosine has been associated with various forms of cancer, including breast cancer, and according to ULB, "reading" DNA hydroxymethylation could provide biomarkers for their detection.

As part of the CANDx project, researchers will perform high-throughput sequencing to gain insight into DNA hydroxymethylation in order to investigate the breast cancer tumors of 100 patients. Longer term, the project aims to detect these biomarkers in the blood of patients, enabling the early detection of cancer and leading to more targeted and effective therapies, ULB said.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.